133 related articles for article (PubMed ID: 16340485)
1. Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
Khanlou H; Bhatti L; Farthing C
J Acquir Immune Defic Syndr; 2006 Jan; 41(1):124-5. PubMed ID: 16340485
[No Abstract] [Full Text] [Related]
2. Meeting report. Report from ICAAC.
Sax PE
AIDS Clin Care; 2006 Dec; 18(12):111-2. PubMed ID: 17228446
[No Abstract] [Full Text] [Related]
3. Reviving protease inhibitors: new data and more options.
Murphy RL
J Acquir Immune Defic Syndr; 2003 Jun; 33 Suppl 1():S43-52; quiz S53, S55-6. PubMed ID: 12946064
[No Abstract] [Full Text] [Related]
4. Low-dose, once-daily atazanavir/ritonavir (200/100): an effective treatment for HIV-infected patients in Thailand.
Chetchotisakd P; Anunnatsiri S
J Acquir Immune Defic Syndr; 2008 Oct; 49(2):230-1. PubMed ID: 18820535
[No Abstract] [Full Text] [Related]
5. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
[TBL] [Abstract][Full Text] [Related]
6. The continuing evolution of HIV therapy.
Boyle BA
AIDS Read; 2003 Dec; 13(12):576-8, 582. PubMed ID: 14959692
[No Abstract] [Full Text] [Related]
7. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
Gianotti N; Galli L; Bocchiola B; Cahua T; Panzini P; Zandonà D; Salpietro S; Maillard M; Danise A; Pazzi A; Lazzarin A; Castagna A
HIV Med; 2013 Mar; 14(3):153-60. PubMed ID: 22994659
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
Calcagno A; Bonora S; Tettoni MC; D'Avolio A; Perri GD; Lanzafame M; Penco G
J Acquir Immune Defic Syndr; 2009 Nov; 52(3):431-2. PubMed ID: 19858926
[No Abstract] [Full Text] [Related]
9. Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort.
Cuzin L; Flandre P; Pugliese P; Duvivier C; Yazdanpanah Y; Billaud E; Poizot-Martin I; Katlama C;
HIV Clin Trials; 2008; 9(3):147-51. PubMed ID: 18547901
[TBL] [Abstract][Full Text] [Related]
10. Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy.
Shuter J; Sarlo JA; Rode RA; Zingman BS
HIV Clin Trials; 2009; 10(3):135-42. PubMed ID: 19632952
[TBL] [Abstract][Full Text] [Related]
11. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients.
Sax PE
AIDS Clin Care; 2003 Sep; 15(9):78. PubMed ID: 14666914
[TBL] [Abstract][Full Text] [Related]
12. An update and review of antiretroviral therapy.
Piacenti FJ
Pharmacotherapy; 2006 Aug; 26(8):1111-33. PubMed ID: 16863488
[TBL] [Abstract][Full Text] [Related]
13. Rescue therapy with once-daily atazanavir-based regimens for antiretroviral-experienced HIV-infected patients.
Dronda F; Antela A; Pérez-Elías MJ; Casado JL; Moreno A; Moreno S
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):258-9. PubMed ID: 16645550
[No Abstract] [Full Text] [Related]
14. Monotherapy with atazanavir as a simplification strategy: results from an observational study.
Cossarini F; Salpietro S; Galli L; Gianotti N; Nozza S; Spagnuolo V; Hasson H; Bossolasco S; Lazzarin A; Tambussi G; Castagna A
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):e101-3. PubMed ID: 22728751
[No Abstract] [Full Text] [Related]
15. Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.
Gyalrong-Steur M; Bogner JR; Seybold U
Eur J Med Res; 2011 Feb; 16(2):85-92. PubMed ID: 21463988
[TBL] [Abstract][Full Text] [Related]
16. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Cordery DV; Hesse K; Amin J; Cooper DA
Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
[TBL] [Abstract][Full Text] [Related]
17. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
[No Abstract] [Full Text] [Related]
18. Initial therapy for human immunodeficiency virus: broadening the options.
Sension M
HIV Clin Trials; 2004; 5(2):99-111. PubMed ID: 15116286
[TBL] [Abstract][Full Text] [Related]
19. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF;
AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
Malan DR; Krantz E; David N; Wirtz V; Hammond J; McGrath D;
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):161-7. PubMed ID: 17971713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
